Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.

Abstract

The recommended starting dose for phase II taxotere trials is 100 mg/m2 administered as a 2-hour infusion, repeated every 21 days. Taxotere is a promising antineoplastic agent worthy of extensive phase II testing in patients with a variety of malignancies.